Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Chimeric Antibodies, Humanized Antibodies), By Application (Blood Cancer, Breast Cancer, Lung Cancer), By End-user, By Region, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1 Research Methodology
                   1.1 Information Procurement
                   1.2 Data Analysis
Chapter 2 Executive Summary
                   2.1 Market Snapshot
Chapter 3 Cancer Monoclonal Antibodies Market Variables, Trends & Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent market outlook
                       3.1.2 Ancillary market outlook
                   3.2 Penetration and Growth Prospect Mapping
                   3.3 Market Segmentation & Scope
                   3.4 Cancer Monoclonal Antibodies Market Analysis Market Dynamics
                   3.5 Market Driver Analysis
                       3.5.1 Growing prevalance of cancer
                       3.5.2 Increasing investement in research and development
                       3.5.3 Rising preference for personalized medicines
                   3.6 Market Restraint Analysis
                       3.6.1 High cost of monoclonal antiobdy therpaeutics
                   3.7 Key Opportunities
                       3.7.1 Booming Biosimilar market
                   3.8 Cancer Monoclonal Antibodies Market - PESTLE analysis
                   3.9 Industry Analysis - Porter’s
                   3.10 Major Deals & Strategic Alliances Analysis
                       3.10.1 Joint ventures
                       3.10.2 Mergers & acquisitions
                       3.10.3 Licensing & partnership
                       3.10.4 Technology collaborations
                       3.10.5 Strategic divestments
                   3.11 COVID-19 Impact Analysis
Chapter 4 Cancer Monoclonal Antibodies Market: Segment Analysis, by Type, 2018 - 2030 (USD Billion)
                   4.1 Cancer Monoclonal Antibodies Market: Type Movement Analysis
                   4.2 Humanized
                       4.2.1 Humanized Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   4.3 Human
                       4.3.1 Human Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   4.4 Chimeric
                       4.4.1 Chimeric Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   4.5 Murine
                       4.5.1 Murine Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
Chapter 5 Cancer Monoclonal Antibodies Market: Segment Analysis, By Application, 2018 - 2030 (USD Billion)
                   5.1 Cancer Monoclonal Antibodies Market: Application Movement Analysis
                   5.2 Blood Cancer
                       5.2.1 Blood Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.3 Breast Cancer
                       5.3.1 Breast Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.4 Lung Cancer
                       5.4.1 Lung Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.5 Melanoma
                       5.5.1 Melanoma Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.6 Colorectal Cancer
                       5.6.1 Colorectal Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.7 Liver Cancer
                       5.7.1 Liver Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   5.8 Others
                       5.8.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
Chapter 6 Cancer Monoclonal Antibodies Market: Segment Analysis, By End-User, 2018 - 2030 (USD Billion)
                   6.1 Cancer Monoclonal Antibodies Market: End-User Movement Analysis
                   6.2 Hospitals
                       6.2.1 Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   6.3 Research Institutes
                       6.3.1 Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
                   6.4 Others
                       6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
Chapter 7 Cancer Monoclonal Antibodies Market: Segment Analysis, By Region, 2018 - 2030 (USD Billion)
                   7.1 Cancer Monoclonal Antibodies Market: Regional Movement Analysis
                   7.2 North America
                       7.2.1 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.2.2 U.S.
                           7.2.2.1 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.2.3 Canada
                           7.2.3.1 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                   7.3 Europe
                       7.3.1 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.3.2 U.K.
                           7.3.2.1 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.3.3 Germany
                           7.3.3.1 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.3.4 France
                           7.3.4.1 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                   7.4 Asia Pacific
                       7.4.1 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.4.2 Japan
                           7.4.2.1 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.4.3 China
                           7.4.3.1 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.4.4 India
                           7.4.4.1 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                   7.5 Latin America
                       7.5.1 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.5.2 Brazil
                           7.5.2.1 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.5.3 Mexico
                           7.5.3.1 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                   7.6 Middle East and Africa (MEA)
                       7.6.1 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.6.2 South Africa
                           7.6.2.1 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
                       7.6.3 Saudi Arabia
                           7.6.3.1 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
Chapter 8 Competitive Landscape
                   8.1 Vendor Landscape
                       8.1.1 Global Cancer Monoclonal Antibody Market: Key Company Market Share Analysis, 2021
                   8.2 Company Profiles
                       8.2.1 F. HOFFMANN-LA ROCHE LTD
                           8.2.1.1 Company overview
                           8.2.1.2 Financial performance
                           8.2.1.3 Product benchmarking
                           8.2.1.4 Pipeline analysis
                           8.2.1.5 Strategic initiatives
                       8.2.2 BRISTOL MYERS SQUIBB CO.
                           8.2.2.1 Company overview
                           8.2.2.2 Financial performance
                           8.2.2.3 Product benchmarking
                           8.2.2.4 Pipeline analysis
                           8.2.2.5 Strategic initiatives
                       8.2.3 MERCK & CO.
                           8.2.3.1 Company overview
                           8.2.3.2 Financial performance
                           8.2.3.3 Product benchmarking
                           8.2.3.4 Pipeline analysis
                           8.2.3.5 Strategic initiatives
                       8.2.4 GLAXOSMITHKLINE PLC
                           8.2.4.1 Company overview
                           8.2.4.2 Financial performance
                           8.2.4.3 Product benchmarking
                           8.2.4.4 Pipeline analysis
                           8.2.4.5 Strategic initiatives
                       8.2.5 JOHNSON & JOHNSON
                           8.2.5.1 Company overview
                           8.2.5.2 Financial performance
                           8.2.5.3 Product benchmarking
                           8.2.5.4 Pipeline analysis
                           8.2.5.5 Strategic initiatives
                       8.2.6 AMGEN, INC.
                           8.2.6.1 Company overview
                           8.2.6.2 Financial performance
                           8.2.6.3 Product benchmarking
                           8.2.6.4 Pipeline analysis
                           8.2.6.5 Strategic initiatives
                       8.2.7 NOVARTIS AG
                           8.2.7.1 Company overview
                           8.2.7.2 Financial performance
                           8.2.7.3 Product benchmarking
                           8.2.7.4 Pipeline analysis
                           8.2.7.5 Strategic initiatives
                       8.2.8 ASTRAZENECA PLC
                           8.2.8.1 Company overview
                           8.2.8.2 Financial performance
                           8.2.8.3 Product benchmarking
                           8.2.8.4 Pipeline analysis
                           8.2.8.5 Strategic initiatives
                       8.2.9 ELI LILLY AND COMPANY
                           8.2.9.1 Company overview
                           8.2.9.2 Financial performance
                           8.2.9.3 Product benchmarking
                           8.2.9.4 Pipeline analysis
                           8.2.9.5 Strategic initiatives
                       8.2.10 ABBVIE
                           8.2.10.1 Company overview
                           8.2.10.2 Financial performance
                           8.2.10.3 Product benchmarking
                           8.2.10.4 Pipeline analysis
                           8.2.10.5 Strategic initiatives

List of Tables

TABLE 1 Cancer monoclonal antibodies market - Industry snapshot & key buying criteria
TABLE 2 Cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 3 Cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 4 Cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 5 Cancer monoclonal antibodies market, by region, 2018 - 2030 (USD Billion)
TABLE 6 North America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 7 North America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 8 North America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 9 U.S. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 10 U.S. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 11 U.S. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 12 Canada cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 13 Canada cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 14 Canada cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 15 Europe cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 16 Europe cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 17 Europe cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 18 U.K. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 19 U.K. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 20 U.K. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 21 Germany cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 22 Germany cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 23 Germany cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 24 France cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 25 France cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 26 France cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 27 Asia Pacific cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 28 Asia Pacific cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 29 Asia Pacific cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 30 Japan cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 31 Japan cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 32 Japan cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 33 China cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 34 China cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 35 China cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 36 India cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 37 India cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 38 India cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 39 Latin America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 40 Latin America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 41 Latin America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 42 Brazil cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 43 Brazil cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 44 Brazil cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 45 Mexico cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 46 Mexico cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 47 Mexico cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 48 MEA cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 49 MEA cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 50 MEA cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 51 South Africa cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 52 South Africa cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 53 South Africa cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 54 Saudi Arabia cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 55 South Abrabia cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 56 South Abrabia cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)

List of Figures

FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain Based Sizing & Forecasting
FIG. 6 QFD Modelling For Market Share Assessment
FIG. 7 Market summary 2022 (USD Billion)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Cancer monoclonal antibodies market analysis, 2018 - 2030 (USD Billion)
FIG. 11 Cancer monoclonal antibodies market dynamics
FIG. 12 Market driver relevance analysis (Current & future impact)
FIG. 13 Global pharmaceutical industry, 2014 - 2022 (USD Billion)
FIG. 14 Market restraint relevance analysis (Current & future impact)
FIG. 15 Key Opportunities
FIG. 16 Cancer monoclonal antibodies market PESTEL analysis
FIG. 17 Porter’s Five Forces Analysis
FIG. 18 Cancer monoclonal antibodies market, type outlook key takeaways (USD Billion)
FIG. 19 Cancer monoclonal antibodies market: Type movement analysis (USD Billion)
FIG. 20 Humanized market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 21 Human market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 20 Chimeric market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 21 Murine market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 22 Cancer monoclonal antibodies market, application outlook key takeaways (USD Billion)
FIG. 23 Cancer M monoclonal antibodies market: Therapeutic application movement analysis (USD Billion)
FIG. 24 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 25 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 26 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 27 Melanoma market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 28 Colorectal cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 29 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 30 Other applications market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 31 Cancer monoclonal antibodies market, end-user outlook key takeaways (USD Billion)
FIG. 32 Cancer monoclonal antibodies market: End-user movement analysis (USD Billion)
FIG. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 34 Research Institutes market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 35 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 36 Regional market place: Key takeaways (USD Billion)
FIG. 37 Cancer monoclonal antibodies market: Regional movement analysis (USD Billion)
FIG. 38 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 39 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 40 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 41 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 42 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 43 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 44 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 45 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 46 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 47 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 48 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 49 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 50 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 51 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 52 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 53 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 54 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)